Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors

Posted on by

The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants NEW YORK, Feb. 8, 2024 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.